An eye drop candidate designed to treat presbyopia has started phase 3 clinical studies, according to a press release from Orasis Pharmaceuticals.
The multicenter, double-masked, parallel-group NEAR-1 and NEAR-2 trials are enrolling about 600 patients with presbyopia in the U.S. to investigate the efficacy and safety of the drop.
“Our proprietary eye drop formulation was designed to achieve the optimal balance between efficacy, safety and comfort. Promising results from our well-powered phase 2b study, along with the recent Series C funding, have paved a promising path for us to advance
Uncategorized